Evidence map›Paper›PMID 28579757›Full record

ReviewDrug design, development and therapy2017

Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.

Maria Gabriella Raimondo, Martina Biggioggero, Chiara Crotti, Andrea Becciolini, Ennio Giulio Favalli

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Drug design, development and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 1 pooled it
9.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 1 synthesis or guideline pooled it, 119 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Proteasome Inhibitors: Potential in Rheumatoid Arthritis Therapy?International journal of molecular sciences · 2025
    Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Inflammation and autoimmune myasthenia gravis.Frontiers in immunology · 2023
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Maria Gabriella RaimondoDepartment of Clinical Sciences and Health Community, Division of Rheumatology, University of Milan.
Martina BiggioggeroDepartment of Clinical Sciences and Health Community, Division of Rheumatology, University of Milan.
Chiara CrottiDepartment of Clinical Sciences and Health Community, Division of Rheumatology, University of Milan.
Andrea BeccioliniDepartment of Rheumatology, Gaetano Pini Institute, Milan, Italy.
Ennio Giulio FavalliDepartment of Rheumatology, Gaetano Pini Institute, Milan, Italy.
University of Milan · ITIstituto Ortopedico Gaetano Pini · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years the use of biotechnological agents has drastically revolutionized the therapeutic approach and the progression of rheumatoid arthritis (RA). In particular, interleukin-6 (IL-6) has been demonstrated as a pivotal cytokine in the pathogenesis of the disease by contributing to both the innate and the adaptive immune system perturbation, and to the production of acute-phase proteins involved in the systemic expression of the disorder. The first marketed IL-6 blocker was tocilizumab, a humanized anti-IL-6 receptor (anti-IL-6R) monoclonal antibody. The successful use of tocilizumab in RA has encouraged the development of other biologic agents specifically targeting the IL-6 pathway, either directed against IL-6 cytokine (sirukumab, olokizumab, and clazakizumab) or IL-6 receptor (sarilumab). One Phase II and six Phase III randomized controlled trials demonstrated a broad efficacy of sarilumab across all RA patient subtypes, ranging from methotrexate (MTX) to tumor necrosis factor inhibitor insufficient responders. In particular, sarilumab as monotherapy demonstrated a clear head-to-head superiority over adalimumab in MTX-intolerant subjects. In addition, compared with tocilizumab, sarilumab showed a similar safety profile with significantly higher affinity and longer half-life, responsible for a reduction of the frequency of administration (every other week instead weekly). All these aspects may be important in defining the strategy for positioning sarilumab in the treatment algorithm of RA. Indeed, observational data coming from post-marketing real-life studies may provide crucial additional information for better understanding the role of sarilumab in the management of the disease. This review summarizes both the biological role of IL-6 in RA and the clinical data available on sarilumab as an alternative therapeutic option in RA patients.

Indexed as

Interleukin-6 InhibitorsAntibodies, Monoclonal, HumanizedAntirheumatic AgentsArthritis, RheumatoidDrug Therapy, CombinationHumansInterleukin-6Receptors, Interleukin-6Signal TransductionTreatment OutcomeAntibodies, Monoclonal, HumanizedAntirheumatic AgentsIL6 protein, humanIL6R protein, humanInterleukin-6Interleukin-6 InhibitorsReceptors, Interleukin-6sarilumabbiologic drugsinterleukin-6monoclonal antibodyrheumatoid arthritissarilumab

Identifiers

PMID28579757
PMCPMC5447699
OpenAlexW2617898708

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.